Quick Facts

• Targeted Conditions: Irritable Bowel Syndrome (IBS), painful diverticular disease, period pain.
• Therapeutic Goal: To provide relief from abdominal discomfort, cramping, and bloating associated with certain conditions.

Alverin Plus is an authorized medication indicated for the management of symptoms associated with specific functional gastrointestinal (GI) disorders and other conditions characterized by smooth muscle spasms.

Its primary therapeutic role is in providing symptomatic relief for individuals with Irritable Bowel Syndrome (IBS). This includes helping to address abdominal pain, discomfort, and feelings of bloating or fullness. The medication is also utilized to contribute to the management of symptoms arising from painful diverticular disease of the colon.

Furthermore, Alverin Plus may be used to help mitigate the discomfort and cramping experienced during menstruation (period pain), which is associated with spasms in the uterine muscle. The medication's intended effect is to support the relaxation of muscles in the gut and uterus, aiding in the reduction of related pain.

Eligibility Map: Who can and cannot use Alverin Plus — official regulatory information

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and adolescents aged 12 years and above [Source: EMA/MHRA].
Populations for whom use is contraindicated	Patients with intestinal obstruction or paralytic ileus [Source: EMA/MHRA].
Age-related eligibility rules	Use is contraindicated in children under the age of 12 years [Source: EMA/MHRA].
Condition-specific eligibility rules	Do not use if known to have hypersensitivity or allergy to alverine citrate or any excipient [Source: EMA/MHRA].
Pregnancy and lactation eligibility status	Use is contraindicated during pregnancy and is not recommended during breastfeeding due to limited safety data [Source: EMA/MHRA].
Eligibility-related restrictions	Use is not advised for those with new symptoms, or symptoms that worsen or do not improve after two weeks of treatment [Source: EMA/MHRA].

---

Eligibility classifications (high-level)

Eligibility severity classification (as defined in official documents): Contraindicated (Paralytic Ileus, Intestinal Obstruction, Hypersensitivity, Pregnancy, Children under 12); Not Recommended (Lactation).

Regulatory basis (EMA / FDA / etc.): EMA/MHRA Summary of Product Characteristics (SmPC).

Eligibility-context constraints (as defined in official documents): Eligibility is constrained by Age, Gastrointestinal Comorbidity, Pregnancy/Lactation Status, and Hypersensitivity.

---

Resulting eligibility structure

Official eligibility statements:

• The medicine is formally contraindicated for any individual with a history of intestinal obstruction or paralytic ileus.
• It is contraindicated for use in children under 12 years of age and throughout the periods of pregnancy and breastfeeding.
• The drug is intended for use in adults and adolescents aged 12 and above, provided there are no contraindicating gastrointestinal conditions or known hypersensitivity.

Connection to the overall eligibility profile (2–4 sentences):

The official label strictly defines eligibility based on a patient’s physiological status and medical history. Contraindications preclude use in specific gastrointestinal disease states and in patients who are pregnant or breastfeeding. The medicine’s use is reserved for eligible adult and adolescent populations (aged 12 and above) who do not present any documented regulatory exclusion.

Interactions with other medicines and products

The official interaction profile for Alverin Plus, as verified and documented by government regulatory bodies, is characterized by the absence of known, clinically significant interactions with other medicinal products or common substances. This section summarizes the findings explicitly stated in authoritative drug labels, such as the Summary of Product Characteristics (SmPC) issued by national health agencies.

The regulatory documents confirm that:

• Drug–Drug Combinations: No specific medicinal products or product classes are explicitly listed as contraindicated or restricted due to an interaction mechanism. The official profile does not include formal contraindicated combinations based on interaction risk.
• Metabolic and Transporter Effects: Official prescribing information does not describe any known interaction patterns involving drug metabolism (such as Cytochrome P450 enzymes) or drug transporters. No exposure-modifying effects (e.g., increased or reduced plasma levels) have been documented when Alverin Plus is co-administered.
• Administration and Substance Constraints: No mandatory timing separation rules for administration are specified in the regulatory texts. Furthermore, official labeling does not specify any interaction constraints with food, alcohol, or herbal products. The overall documentation states that no specific interaction constraints are currently known or imposed.

Dual Mechanism: Neuro-Disruption and Metabolic Blockade

This combination relies on two distinct and complementary mechanistic domains to exert its biological activity against various parasites. The active components engage separate vulnerabilities: ion channels in the nervous system and enzymes in the metabolic pathway. This combination addresses parasitic targets using distinct mechanistic strategies.

Ivermectin: Targeted Neuromuscular Paralysis

The Ivermectin component initiates a cascade by acting as a high-affinity agonist on Glutamate-gated Chloride Channels ( GluCl) found exclusively in nematode and arthropod nerve and muscle cells. This molecular binding causes an immediate, sustained influx of chloride ions, resulting in the hyperpolarization of the parasite's nerve cells. This physiological event immediately halts all necessary signal transmission, leading directly to the parasite's irreversible flaccid paralysis and subsequent death.

Clorsulon: Fluke-Specific Energy Depletion

The Clorsulon component employs an entirely different mechanism, focusing on metabolic inhibition against adult liver flukes. It acts as a competitive inhibitor of key glycolytic enzymes (3-phosphoglycerate kinase and phospho-glyceromutase), thereby blocking the fluke's ability to utilize glucose for energy. This action rapidly produces a profound depletion of cellular ATP, resulting in metabolic stress that causes structural failure, which results in the death of the fluke.

General Principles of Administration

Alverin Plus (Ivermectin and Clorsulon) is administered as a single-dose treatment designed for a precise application protocol. The official method is by subcutaneous injection; administration through the intravenous or intramuscular routes is expressly forbidden.

Dosing and Weight-Based Calculation

The dosing regimen is determined by the animal's body weight to ensure accurate delivery of the active ingredients. The labeled standard requires 1 mL per 50 kg of animal mass, which corresponds to the doses of 200 mug/kg of Ivermectin and 2 mg/kg of Clorsulon.

Parameter	Official Guideline
Route	Subcutaneous injection only
Standard Dose	1 mL per 50 kg body weight
Frequency	Single-dose treatment
Administration Site	Subcutaneously behind the shoulder

Procedural and Population Constraints

The administration procedure requires attention to volume constraints. Any dose volume greater than 10 mL must be divided and administered into two separate injection sites to maintain proper procedural standards. Guidelines limit the eligible population to beef cattle and non-lactating dairy cattle. Use is specifically prohibited in lactating cows and in any animals intended for veal. The product may also need to be warmed to approximately 15°C before injection if stored in a cold environment to ensure proper flow and administration.

Research evidence / Overview of studies for Alverin Plus

Evidence for Use in Irritable Bowel Syndrome (IBS)

Research for Alverin Plus has primarily focused on exploring how symptoms change over time in Irritable Bowel Syndrome (IBS). These studies involved adult patients and utilized Randomized Controlled Trials (RCTs), comparing the medicine against a placebo or other existing treatments. The trials evaluated patient-reported outcomes describing perceived discomfort, focusing on scores for abdominal pain and bloating. Systematic reviews contribute to the broader evidence landscape for this condition. Findings describe patterns observed in studies related to measurements of change during the short-term treatment period.

Research for Other Spasm-Related Conditions

Research has also explored the medicine's profile in treating conditions associated with acute episodes of smooth muscle spasm, specifically painful diverticular disease and Primary Dysmenorrhea (period pain). For painful diverticular disease, dedicated comparative evidence is lacking; evidence contributes to understanding symptom patterns based on the medicine's pharmacological classification. For Primary Dysmenorrhea, controlled clinical studies were evaluated, examining outcomes related to pain intensity. However, scientific literature indicates the evidence remains limited, and a need for more extensive research exists.

Duration of Study and Long-Term Evidence

Clinical research has explored short-term symptom changes, typically monitoring responses over defined time intervals lasting a few weeks, though some studies extended up to six months. The existing evidence contributes to understanding short-term changes, but there is limited information for long-term outcomes. Long-term effects are not fully established.

Research in Specific Patient Groups and Gaps

The majority of research was evaluated in the adult population, particularly groups where female participants were more frequently represented, as seen in IBS trials. Data for groups outside the general adult population, such as children or older adults (geriatric patients), remain insufficient. The research highlights several areas of uncertainty: follow-up durations were often limited, comparative evidence is lacking for certain indications like painful diverticular disease, and research does not determine whether an individual will respond similarly to the group patterns observed.

Key Studies & References

1. Routine clinical administration of 4-week alverine citrate and simeticone combination relief global IBS symptoms
2. Summary of Product Characteristics (SmPC) for Alverine Citrate (General Indication/Profile Source)

Common questions about Alverin Plus (FAQ)

---

Q: What is the withdrawal period for meat following administration?

Official regulatory documents specify a required withdrawal period to ensure safety for human consumption. Cattle should not be slaughtered for human consumption within 21 days of receiving this product. Official information also notes that a withdrawal period has not been established for pre-ruminating calves.

---

Q: What should I do if the animal experiences an injection site reaction?

Official product information notes that some animals may experience temporary discomfort or soft tissue swelling at the injection site. These reactions are typically short-lived and often resolve on their own without the need for treatment. Official procedural standards note that dose volumes greater than 10 mL must be divided and administered into two separate injection sites.

---

Q: How should I dispose of partially used bottles or waste material?

To maintain product stability and safety, official labels define the in-use life of the container after the first puncture. Regulatory guidelines state that all unused medicine and waste material requires disposal in accordance with local environmental regulations, typically involving an approved landfill or incineration, to minimize harm to aquatic organisms.

---

Q: What is the shelf life after the product has been first opened (in-use stability)?

Official labels define the in-use stability, which is the amount of time the product can be used after the vial is first punctured. This period is set for specific package sizes. It is important to adhere to the number of months specified for use after the initial puncture.

---

Q: Is a prescription or veterinary authorization required to purchase this product?

This product is a veterinary medicine and is generally classified as a 'Restricted Drug' or similar category in many jurisdictions. Official product information suggests that its use requires consultation with a veterinarian for assistance in the treatment and control of parasitism.

---

Q: What happens if I accidentally inject the medicine intravenously?

Official administration guidelines state that the product is for subcutaneous injection only, and administration through the intravenous or intramuscular routes is expressly forbidden. The regulatory labels do not detail the specific consequences or actions required following accidental use by a non-approved route.

---

Q: How long after injection does it take for the drug to start working?

Pharmacokinetic studies describe different absorption rates for the two active components, Clorsulon and Ivermectin. This means the components may reach their highest concentrations in the animal’s system at different times. Furthermore, the drug is designed to provide persistent activity, meaning it can continue to control certain infections acquired for up to several weeks after the initial treatment.

---

Q: What specific parasitic conditions or worms does Alverin Plus treat?

According to official product information, this combination is indicated for the control and treatment of a broad range of parasites. This includes both internal parasites, such as gastrointestinal roundworms, lungworms, and adult liver flukes, and external parasites, such as various sucking lice and mange mites. The combination is effective against numerous species and stages of these parasitic infections.

---

Q: Is Alverin Plus safe for all types of livestock, like calves or non-beef animals?

The product is officially developed and approved for use in cattle only. Regulatory information strictly prohibits its administration to other animal species because severe adverse reactions, including fatalities, may result. Use is strictly prohibited in veal calves. For pre-ruminating calves, official labels state that a withdrawal period has not been established.

How to Store and Dispose of Alverin Plus?

The storage and disposal of this medicine are defined by official regulatory labeling to maintain stability and ensure safety.

Mandatory Storage Conditions

Requirement	Official Statement
Temperature	Do not store above mathbf25 C or mathbf30 C (depending on the product variation).
Protection	Keep in the original container to protect from light and moisture (store in a dry place).
Safety	Keep out of the reach of children.

Stability and Handling

• Shelf Life: The product must not be used after the expiry date stated on the package.
• Handling: The medicine should remain in its original outer carton until use.

Disposal Instructions

Any unused Alverin Plus or waste material must be disposed of properly. This disposal must be carried out in accordance with local requirements for pharmaceutical waste to prevent environmental harm.